Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation and chemotherapy. However, these treatments are fraught with side effects, especially for children. A recent study points to a new treatment strategy that takes advantage of the body’s own immune response.
Read about the new study at Pediatrics Nationwide: Combining Immunotherapies Effective Against Mouse Model of Cancer.